— Know what they know.
Not Investment Advice
Also trades as: 0LB2.L (LSE) · $vol 0M

SUPN NASDAQ

Supernus Pharmaceuticals, Inc.
1W: -0.7% 1M: -8.2% 3M: -12.1% YTD: -17.2% 1Y: -22.5% 3Y: +68.5% 5Y: +38.1%
$40.96
+0.19 (+0.47%)
After Hours: $44.62 (+3.66, +8.95%)
Weekly Expected Move ±6.0%
$36 $38 $41 $43 $46
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 38 · $2.4B mcap · 55M float · 1.57% daily turnover · Short 58% of daily vol
Credit Risk of going bust: lower than 91% of companies Debt: 1.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 99.9%), Supernus Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $40.2M against a stock market value of $2.37B.
Distance to default 14.33 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $10.7M (short-term plus half of long-term), stock volatility 37.7%; Altman Z 4.66. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$1.5B +6.2% ▲
5Y CAGR: -0.7%
Total Liabilities
$391M +17.6% ▲
5Y CAGR: -12.4%
Shareholders Equity
$1.1B +2.5% ▲
5Y CAGR: +7.3%
Cash & Investments
$309M -32.0% ▼
5Y CAGR: -6.1%
Total Debt
$41M +19.6% ▲
5Y CAGR: -37.0%
Net Debt
-$87M -149.5% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$203M$93M$75M$69M$128M
Short-Term Investments$136M$368M$180M$384M$180M
Cash & ST Investments$340M$461M$255M$454M$309M
Net Receivables$149M$165M$144M$142M$188M
Inventory$86M$92M$77M$54M$82M
Other Current Assets$0$16M$17M$36M$65M
Total Current Assets$602M$734M$493M$686M$644M
Property, Plant & Equip.$17M$15M$14M$12M$11M
Goodwill & Intangibles$902M$819M$717M$639M$694M
Long-Term Investments$119M$94M$17M$0$0
Other Non-Current Assets$49M$40M$38M$32M$65M
Total Non-Current Assets$1.1B$968M$785M$682M$808M
Total Assets$1.7B$1.7B$1.3B$1.4B$1.5B
— Liabilities —
Accounts Payable$9M$11M$2M$5M$3M
Short-Term Debt$0$402M$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$93M$55M$77M$69M$99M
Total Current Liabilities$315M$688M$290M$292M$338M
Long-Term Debt$379M$0$0$0$0
Other Non-Current Liab.$52M$43M$8M$8M$22M
Total Non-Current Liabilities$558M$128M$66M$40M$53M
Total Liabilities$873M$816M$356M$332M$391M
— Equity —
Common Stock$53K$54K$55K$56K$57K
Retained Earnings$380M$481M$483M$556M$518M
Accumulated OCI$2M-$3M-$593K-$189K-$44K
Total Stockholders Equity$816M$886M$922M$1.0B$1.1B
Total Liabilities & Equity$1.7B$1.7B$1.3B$1.4B$1.5B
— Key Metrics —
Total Debt$427M$445M$42M$34M$41M
Net Debt$224M$352M-$34M-$35M-$87M
Total Investments$255M$462M$196M$384M$180M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms